Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs

By Sheffield Leslie J   Irving Peter   Gupta Arun   Byron Keith   Macrae Finlay A   Phillimore Hazel   Dronavalli Mithilesh   Rose Rosemary   George Peter   Walmsley Trevor   Dixon Barbara   Poole Susan   Dooley Michael   Sparrow Miles  

Pharmacogenomics, Vol. 10, Iss. 7, 2009-07 ,pp. : 1091-1099

Future Medicine

Access to resources Recommend Favorite

Thiopurine Treatment in Inflammatory Bowel Disease

By Gardiner Sharon J.  

Clinical Pharmacokinetics, Vol. 46, Iss. 9, 2007-01 ,pp. : 803-804

Adis International

Access to resources Recommend Favorite

New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients

By Zabala William   Cruz Raquel   Barreiro-de Acosta Manuel   Chaparro María   Panes Julián   Echarri Ana   Esteve Maria   Carpio Daniel   Andreu Montserrat   García-Planella Esther   Domenech Eugeni   Carracedo Angel   Gisbert Javier P   Barros Francisco  

Pharmacogenomics, Vol. 14, Iss. 6, 2013-04 ,pp. : 631-640

Future Medicine

Access to resources Recommend Favorite

Allopurinol–thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?

By Roberts Rebecca L   Gearry Richard B   Barclay Murray L  

Pharmacogenomics, Vol. 11, Iss. 11, 2010-11 ,pp. : 1505-1508

Future Medicine

Access to resources Recommend Favorite

Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease and Established Azathioprine Therapy

By L.P.L. Gilissen  

Clinical Drug Investigation, Vol. 24, Iss. 8, 2004-01 ,pp. : 479-486

Adis International

Access to resources Recommend Favorite